Combinational Therapy of Cardiac Atrial Appendage Stem Cells and Pyridoxamine: The Road to Cardiac Repair?

Lize Evens1, Hanne Beliën1, Sarah D'Haese1

  • 1UHasselt-Hasselt University, BIOMED-Biomedical Research Institute, Agoralaan, 3590 Diepenbeek, Belgium.

Insights

Pyridoxamine (PM) did not improve cardiac regeneration in rats after myocardial infarction (MI) when combined with cardiac atrial appendage stem cells (CASCs). While PM reduced advanced glycation end products (AGEs), it did not enhance the benefits of CASCs therapy for heart repair.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Biochemistry

Background:

  • Myocardial infarction (MI) leads to irreversible cardiomyocyte loss and heart failure progression.
  • Current therapies for MI are insufficient for cardiac regeneration.
  • Cardiac atrial appendage stem cells (CASCs) show promise for cellular therapy post-MI.

Purpose of the Study:

  • To investigate if pyridoxamine (PM) enhances CASC transplantation efficacy after MI.
  • To determine if PM reduces advanced glycation end products (AGEs) in the cardiac environment.
  • To assess PM's impact on cardiac function and regeneration post-MI.

Main Methods:

  • MI induced in rats via coronary artery ligation.
  • Groups: No therapy, CASCs transplantation, CASCs + PM treatment.
  • Evaluated cardiac function, infarct size, collagen deposition, and cardiomyocyte contractility.

Main Results:

  • CASCs transplantation improved cardiac function and reduced infarct size.
  • CASCs prevented deterioration of cardiomyocyte contractile properties.
  • PM reduced cardiac AGEs but did not further improve cardiac outcomes compared to CASCs alone.

Conclusions:

  • Pyridoxamine (PM) did not enhance the regenerative effects of CASCs transplantation post-MI.
  • Reducing AGEs with PM did not improve cardiac outcomes in this stem cell therapy model.
  • The role of AGEs in stem cell therapy efficacy after MI requires further investigation.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
79
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
67
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
57
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
845